Increases efficiency, reproducibility, and accuracy i in the electro-anatomical maps electrophysiologists use in catheter ablation procedures IRVINE, Calif., May 8, 2024 /PRNewswire/ -- Biosense ...
Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium
IRVINE, Calif., Feb. 2, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, announced 12-month results from the company ...
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the new CARTO® 3 MEM (Multi-Electrode Mapping)Version in the United States.
Johnson & Johnson MedTech’s Biosense Webster division has tallied up another regulatory clearance for its pulsed field ablation system, with a CE mark opening up access to Europe. The Varipulse ...
First regulatory approval for the first-of-its-kind, fully-integrated PFA system with a simple and reproducible workflow Integrated with the world's leading CARTO™ 3D cardiac mapping system for the ...
Biosense Webster Inc. reported U.S. FDA approval of its Thermocool Smarttouch SF ablation catheter for the treatment of patients with persistent atrial fibrillation (persistent AF). This follows ...
The heart beat is controlled by a system of electrical signals spreading from the top of the heart to the bottom. The electrical signal is initiated in an area of the upper right chamber, called the ...
IRVINE, Calif., April 21, 2026--(BUSINESS WIRE)--Johnson & Johnson today announced it will showcase the latest advances across its electrophysiology portfolio at the 2026 Heart Rhythm Society (HRS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results